We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

56 hedge funds and large institutions have $1.02M invested in Navidea Biopharmaceuticals Inc. in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

6% more funds holding

Funds holding: 53 → 56 (+3)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

74% less capital invested

Capital invested by funds: $3.91M → $1.02M (-$2.9M)

Holders
56
Holders Change
+3
Holders Change %
+5.66%
% of All Funds
1.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
6
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
+$13.1K
2
CAG
Csenge Advisory Group
Florida
+$8.24K
3
Millennium Management
Millennium Management
New York
+$4.04K
4
SS
Simplicity Solutions
Minnesota
+$3.13K
5
Bank of America
Bank of America
North Carolina
+$2.58K

Top Sellers

Rank Fund Capital Flow
1
CWM
Cornerstone Wealth Management
Missouri
-$1.13M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$282K
3
HIIFS
Harel Insurance Investments & Financial Services
Israel
-$180K
4
SFS
Sowell Financial Services
Arkansas
-$55K
5
Goldman Sachs
Goldman Sachs
New York
-$31K
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
26
Invesco
Georgia
$4K -$437 -106 -6%
Citigroup
27
Citigroup
New York
$4K – – –
CAG
28
Csenge Advisory Group
Florida
$4K +$8.24K +2,000 New
Commonwealth Equity Services
29
Commonwealth Equity Services
Massachusetts
$3K – – –
LFG
30
LifePlan Financial Group
Ohio
$3K – – –
USAA
31
United Services Automobile Association
Texas
$3K – – –
JP Morgan Chase
32
JP Morgan Chase
New York
$3K +$1.03K +250 +24%
HC
33
Hamilton Capital
Ohio
$2K – – –
JCM
34
Jacobi Capital Management
Pennsylvania
$2K – – –
LA
35
Lynch & Associates
Indiana
$2K – – –
MCG
36
McCollum Christoferson Group
New York
$2K – – –
PNC Financial Services Group
37
PNC Financial Services Group
Pennsylvania
$2K – – –
RJA
38
Raymond James & Associates
Florida
$2K – – –
SS
39
Simplicity Solutions
Minnesota
$2K +$3.13K +760 New
MAFM
40
Mid Atlantic Financial Management
Pennsylvania
$2K +$3.25K +788 New
Millennium Management
41
Millennium Management
New York
$2K +$4.04K +981 New
MWPCG
42
Measured Wealth Private Client Group
New Hampshire
$1K -$206 -50 -8%
ASN
43
Advisory Services Network
Georgia
$1K – – –
AWM
44
Aevitas Wealth Management
Massachusetts
$1K – – –
B
45
Bailard
California
$1K – – –
BO
46
BRR OpCo
Ohio
$1K – – –
CIBC World Market
47
CIBC World Market
Ontario, Canada
$1K – – –
SIS
48
Sound Income Strategies
Florida
$1K – – –
TW
49
TrinityPoint Wealth
Connecticut
$1K +$2.06K +500 New
HIIFS
50
Harel Insurance Investments & Financial Services
Israel
– -$180K -39,000 Closed
1
2
3

NAVB Hedge Fund Activity: Q4 2018 in Review

56 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q4 2018, worth a combined $1.02M — down 74% from $3.91M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new NAVB positions and 7 closed out — a net gain of 3 holders — while 6 added to existing stakes and 7 trimmed.

The largest buyer was Two Sigma Securities, opening a new position worth an estimated $13.1K. The largest seller was Cornerstone Wealth Management, exiting entirely with an estimated $1.13M sold.

  • 56 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q4 2018, up from 53 in Q3 2018.
  • Funds reported $1.02M of Navidea Biopharmaceuticals Inc. stock for Q4 2018, down 74% quarter-over-quarter.
  • 10 funds opened new Navidea Biopharmaceuticals Inc. positions in Q4 2018 and 7 closed out, a net change of +3 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q4 2018 was Two Sigma Securities, an estimated $13.1K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q4 2018 was Cornerstone Wealth Management, an estimated $1.13M sold.

Based on aggregated 13F filings for Q4 2018.